Galmed and Tissue Dynamics Uncover Novel Pathway in Cardiac Fibrosis

REHOVOT and RAMAT-GAN, Israel, June 2, 2026

Galmed Pharmaceuticals and Tissue Dynamics have announced a significant preclinical breakthrough in cardiovascular medicine with the discovery of a previously unknown metabolic pathway linked to cardiac fibrosis and heart failure, providing new scientific support for the development of Aramchol Meglumine as a potential treatment for fibrotic heart disease. Using advanced human cardiac organoid technology and artificial intelligence-driven analysis, researchers identified a human-specific disease mechanism that is not readily detectable through conventional animal models. The findings demonstrated that a combination of Aramchol Meglumine, a stearoyl-CoA desaturase 1 (SCD1) inhibitor, and a selective PPARα agonist significantly reduced cardiac fibrosis while preserving heart muscle integrity and metabolic function. The breakthrough highlights the growing role of human organoid platforms and machine learning technologies in uncovering previously hidden disease pathways and accelerating the development of innovative therapies for conditions with substantial unmet medical needs. Cardiac fibrosis remains a major contributor to heart failure progression worldwide, and the newly identified mechanism may open the door to a new generation of targeted therapeutic approaches.

Human Cardiac Organoids Reveal Previously Hidden Disease Biology

Cardiac fibrosis develops when excessive scar tissue accumulates within the heart muscle, leading to impaired cardiac function, reduced elasticity, and progressive heart failure. Despite advances in cardiovascular treatment, no approved therapies currently exist that directly reverse established cardiac fibrosis. One of the greatest challenges facing researchers has been the inability of conventional animal models to accurately replicate the complex physiology and metabolic characteristics of the human heart.

To address this limitation, Tissue Dynamics utilized its DynamiX® robotic platform and highly sophisticated human cardiac organoid systems capable of mimicking critical aspects of human cardiac structure and disease progression. These laboratory-grown heart tissues include multiple chambers, vascular structures, pacemaker cells, and specialized tissue layers, enabling researchers to study disease mechanisms in a clinically relevant environment. Through this advanced model, investigators identified a previously unrecognized metabolic pathway associated with mitochondrial stress and abnormal lipid metabolism that appears to play a central role in the development and progression of cardiac fibrosis.

Aramchol Combination Therapy Demonstrates Strong Anti-Fibrotic Activity

The study evaluated the therapeutic impact of combining Aramchol Meglumine with a selective PPARα agonist in inflammatory human cardiac organoids designed to replicate the pathological environment observed in fibrotic heart disease. Results revealed that the combination therapy reduced fibrotic burden by approximately four-fold, achieving highly significant statistical outcomes while simultaneously preserving cardiac muscle density and maintaining normal metabolic activity.

Researchers determined that the therapy effectively modulates two major drivers of disease progression—mitochondrial dysfunction and pathological lipogenesis—which together contribute to tissue scarring and declining cardiac performance. By targeting these interconnected biological pathways, the treatment demonstrated the potential to address the underlying mechanisms responsible for fibrosis rather than merely managing symptoms. The findings suggest that Aramchol-based combination therapy could represent a novel therapeutic strategy for patients with heart failure driven by fibrotic remodeling, a condition affecting millions of individuals worldwide.

Artificial Intelligence Accelerates Discovery of Next-Generation Therapies

A key element of the research was the integration of Tissue Dynamics’ MechaniX® artificial intelligence platform, which enabled investigators to identify and validate the newly discovered metabolic pathway responsible for the observed therapeutic synergy. The AI-powered system combines real-time metabolic analytics, predictive modeling, and explainable machine learning to uncover biological relationships that may be difficult to detect using traditional research methods. Based on the strength of the findings, a new patent application has already been filed, and preparations are underway to support future IND-enabling studies aimed at advancing the program toward clinical development.

Beyond cardiac fibrosis, researchers believe the platform may uncover additional treatment opportunities across broader cardiometabolic and fibrotic diseases. The collaboration between Galmed and Tissue Dynamics demonstrates how combining human-relevant organoid models with advanced computational biology can significantly enhance drug discovery and improve the likelihood of successful clinical translation. As cardiovascular disease remains a leading cause of mortality globally, innovative approaches capable of identifying novel therapeutic targets may play a crucial role in shaping the future of precision medicine and regenerative cardiology.

Source: Galmed Pharmaceuticals press release